Goodrx Holdings, Inc. Stock Price, News & Analysis

GoodRx (Nasdaq: GDRX) will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025.

The company will host a conference call and webcast to discuss results and outlook on Wednesday, November 5, 2025 at 5:00 a.m. PT (8:00 a.m. ET). Telephone participants should call (800) 715-9871 at least 10 minutes early and use conference ID 9085550. The live webcast and accompanying materials will be available on the company investor relations site at https://investors.goodrx.com, with an archived recording posted for at least 30 days approximately one hour after the call.

GoodRx (Nasdaq: GDRX) announced on October 6, 2025 a collaboration with Amgen to offer Repatha (evolocumab) at a cash price of $239 at more than 70,000 pharmacies nationwide, described as nearly 60% savings off the retail list price. The program aims to expand access by providing a lower out-of-pocket option that can bypass certain insurance hurdles such as restrictive formularies and high deductibles. GoodRx highlighted its consumer reach (nearly 30 million users annually) and historical savings of over $85 billion since 2011. Additional patient financial support is available through Amgen's support program.

GoodRx (NASDAQ: GDRX) has announced the launch of RxSmartSaver, its brand medication savings solution, at Kroger's 2,200 pharmacies across 35 states. The program provides instant access to savings on brand-name medications through copay cards, patient assistance programs, and 80+ unique cash prices.

The solution allows customers to scan a code at the pharmacy counter with their smartphone to access savings on essential treatments like Dexcom G7, Humira Biosimilar, Lantus, Ozempic, and Wegovy. This turnkey solution aims to improve pharmacy profitability while making medications more affordable for consumers.

The expansion follows GoodRx's successful pilot with Hy-Vee and aligns with the company's 2025 initiatives, including a new e-commerce experience and Community Link pricing model for independent pharmacies. Since 2011, GoodRx has helped Americans save over $85 billion on medication costs.

GoodRx (NASDAQ: GDRX), America's leading medication savings platform, has launched "The Savings Wrangler," its first brand campaign in three years. The campaign features a cowgirl heroine and her sidekick Dusty Pete, who help Americans navigate high prescription costs.

Developed in-house, this creative initiative aims to transform traditional healthcare advertising through character-driven storytelling. The campaign will debut with a TV spot on August 30, followed by a Times Square subway station takeover on September 22. The multi-channel rollout includes CRM, social media, streaming video, and web platforms.

GoodRx, which has helped Americans save over $85 billion on medications since 2011, serves nearly 30 million consumers and over one million healthcare professionals annually. The campaign represents a strategic move to enhance brand awareness and cultural relevance while maintaining the company's mission of making medication savings accessible.

GoodRx (NASDAQ: GDRX) has announced a groundbreaking collaboration with Novo Nordisk to offer Ozempic® and Wegovy® (semaglutide) pens to eligible self-paying patients for $499 per month. This marks the first time Ozempic® has been available at this self-pay price point.

The initiative addresses significant demand, with nearly 17 million people seeking GLP-1 medication information on GoodRx last year, representing a 22% year-over-year increase. The program will be available at over 70,000 retail pharmacies nationwide, particularly benefiting the estimated 19 million people lacking coverage for GLP-1s prescribed for weight loss.

GoodRx (NASDAQ:GDRX), the leading U.S. medication savings platform, reported Q2 2025 results with revenue of $203.1 million, up 1% year-over-year. The company achieved net income of $12.8 million with a 6.3% margin and Adjusted EBITDA of $69.4 million with a 34.2% margin.

While Pharma manufacturer solutions revenue grew significantly by 32% to $35.0 million, prescription transactions revenue declined 3% to $143.1 million, and subscription revenue fell 7% to $20.5 million. The company faces headwinds from Rite Aid's bankruptcy and volume reduction in an integrated savings program, expecting a $35-40 million revenue impact in 2025. During Q2, GoodRx repurchased 10.2 million shares for $46.4 million.

For FY2025, management expects revenue growth over 2024's $792.3 million and Adjusted EBITDA between $265-275 million, representing 2-6% growth.

GoodRx (NASDAQ: GDRX), America's leading medication savings platform, has appointed Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. Jensen joins from Amazon Pharmacy, where she served as Head of Manufacturer & Prescriber Business Development, bringing extensive experience in pharmaceutical partnerships and patient access innovation.

Jensen will lead GoodRx's Pharma Manufacturer Solutions division, leveraging her background at companies like UCB and GlaxoSmithKline to enhance pharmaceutical partnerships. GoodRx, which has helped Americans save over $85 billion on medications since 2011, serves nearly 30 million consumers and over one million healthcare professionals annually.

GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025 after market close.

The company will host a conference call and webcast on Thursday, August 7, 2025 at 5:00 AM PT (8:00 AM ET) to discuss the quarterly results and business outlook. Interested participants must pre-register to receive dial-in details. The webcast will be available on the company's investor relations website, with materials posted before the call and an archived version accessible for at least 30 days afterward.

GoodRx (GDRX) has launched a new subscription service for erectile dysfunction (ED) treatment, offering an all-in-one solution starting at $18/month. The service includes virtual consultations with licensed healthcare professionals, FDA-approved prescription medications, and discreet home delivery. According to GoodRx's research, while nearly 1 in 3 U.S. men report ED issues, only 14% seek treatment due to barriers like high costs, social stigma, and inadequate insurance coverage. The new service aims to eliminate these obstacles by providing quick online consultations, often within an hour, transparent pricing with no hidden fees, and convenient home delivery in standard packaging. This initiative aligns with GoodRx's mission to make healthcare more accessible and affordable, building on their track record of helping Americans save over $85 billion on medication costs since 2011.